Impact of previous anti-angiogenesis treatment in nivolumab-treated advanced non-small cell lung cancer

Abstract

Aim: To investigate how previous systemic therapy such as anti-angiogenesis can influence cancer immunotherapy for non-small cell lung cancer (NSCLC).

Methods: A total of 134 patients with advanced NSCLC who were treated with nivolumab were retrospectively reviewed. Correlation between status of prior anti-angiogenesis treatment and clinical characteristics were determined. Impact of prior anti-angiogenesis on therapeutic outcome of nivolumab was investigated for tumor efficacy such as progression free survival (PFS).

Results: Sixteen patients were treated with at least one anti-angiogenesis agent prior to nivolumab. The prior use of antiangiogenesis agent was associated with stage IV disease, non-squamous histology, and two or more lines of systemic therapy. Median PFS was significantly shorter in the prior anti-angiogenesis group than in no prior anti-angiogenesis group (8.3 vs. 11.3 weeks, log-rank P = 0.006). Multivariate analyses demonstrated that only prior anti-angiogenesis status was associated with worse PFS. There is also a slight trend for worse disease control rate (P = 0.101, Fisher’s exact test) and overall survival (P = 0.200, log-rank) in prior anti-angiogenesis group.

Conclusion: This retrospective study suggests that prior anti-angiogenesis treatment negatively impacts the therapeutic outcome of immunotherapy in advanced NSCLC.

Document Type

Article

Publication Date

2018

Publication Title

J Cancer Metastasis Treat

Comments

DOI: 10.20517/2394-4722.2017.65

Link to Full Text

Share

COinS